Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Continued Petitions

Diabetes (Continuous Glucose Monitoring Sensors) (PE1619)

Thursday 28 June 2018 Public Petitions Committee About 09:30–10:15 Petitions 86 contributions · 10 speakers

Speakers

Choose an MSP to read only their contributions

The record

86 contributions
Johann Lamont Lab The Convener · Glasgow
link

The next item on the agenda is consideration of continued petitions. We last considered PE1619, by Stuart Knox, on access to continuous glucose monitoring at our meeting in March, when we agreed to write to the Scottish Government, national health service boards, the Scottish Intercollegiate Guidelines Network and the petitioner. Responses have now been received and are included in our meeting papers.

Members will recall that we agreed to invite the Scottish Government to provide evidence on the petition. It was anticipated that the Cabinet Secretary for Health and Sport, Shona Robison, would be in attendance for today’s evidence session. However, as members will be aware, the cabinet secretary resigned from her position on Tuesday this week and therefore will not be present at our meeting today. We record our thanks to Shona Robison, who has been willing to engage with the Public Petitions Committee on her responsibilities as cabinet secretary and we wish her well in her new role.

I am however pleased to welcome from the Scottish Government Professor Jason Leitch, national clinical director for healthcare quality and strategy; Gillian Gunn, team leader with the strategic planning and clinical priorities team; and Richard Shearer, senior policy officer in that team. Thank you for attending. You have up to five minutes to make an opening statement if you wish to do so, after which we will move to questions from the committee.

Professor Jason Leitch Scottish Government
link

Thank you for having us. Forgive the short-notice change of personnel.

I will outline the position and will then be happy to take questions as best I can. I know how difficult it can be to manage diabetes. I am a dentist and oral surgeon. I am a clinician and have been for 26 years. With that in mind, we must ensure that health technologies have clear evidence of their safety and clinical and cost effectiveness with appropriate evidence-based guidelines on their use.

Before we go further, perhaps I should clarify the difference between two technologies, although I am sure that members have grasped this over their months of looking at the subject. The technologies are continuous glucose monitors and flash glucose monitors—FreeStyle Libre is the example that the committee has been looking at. They are two different types of device. Without going into technical details, continuous glucose monitors have a strong evidence base. They provide alarms and warnings of impending hypoglycaemic attacks and can be used in conjunction with insulin pumps. FreeStyle Libre, a flash glucose monitor, cannot be used like that. It does not provide real-time continuous glucose monitoring or alarms.

We took the step of referring the topic to the Scottish health technologies group, which is an organisation that looks independently at the available evidence clinically and cost effectively. The current position is that seven NHS boards have included FreeStyle Libre in their local formulary. I look forward to the advice statement from the health technologies group, which I expect in July, to assist the remaining NHS boards to identify how they might best consider adoption of the technology in an open, equitable and manageable process.

We have encouraged those boards who have introduced it to share their experience with other boards, and we have asked those boards to ensure that they accurately record the introduction of all diabetes devices into our Scottish care information diabetes collaboration, which is one of our best e-health and technology systems, to help to inform that developing evidence base.

I am happy to take any questions.

Johann Lamont Lab The Convener · Glasgow
link

Thank you. I welcome Emma Harper MSP for this item.

One of the issues that the committee heard during its fact-finding visit on the petition last year was that there had been delays in NHS boards receiving the initial £2 million funding during 2017-18. Can you respond to that?

Professor Leitch
link

I will let Gillian Gunn deal with the delay, although I would put that word in inverted commas. The funding was for continuous glucose monitoring and pumps, not for flash glucose monitoring. They are two different things. The funding that went to the NHS boards was for continuous glucose monitoring and insulin pumps.

Johann Lamont Lab The Convener · Glasgow
link

You talked about putting the word in inverted commas. Are you arguing that there was no delay?

Professor Leitch
link

No. I simply do not know, which is why I wanted you to ask Gillian Gunn.

Gillian Gunn Scottish Government
link

There has been no delay in issuing the funds that were announced and committed to by ministers. The funds went out on time for the beginning of the 2017 financial year and again in this financial year.

Johann Lamont Lab The Convener · Glasgow
link

Somebody has got it wrong then. There has not been a delay.

Gillian Gunn Scottish Government
link

There has been no delay in the Scottish Government issuing the funds to all health boards as described in the director’s letters of last year and this year.

Johann Lamont Lab The Convener · Glasgow
link

We received evidence from NHS Forth Valley that it had to revise how it planned to spend the allocated funding because VAT was not included. Can you clarify that and say whether the guidance is sufficiently clear about the actual funding that is available to health boards?

Gillian Gunn Scottish Government
link

The funding that was allocated to the boards for insulin pumps and continuous glucose monitors did not include VAT. Boards have funded the VAT from their own resources. The funding for insulin pumps and continuous glucose monitors is to buy the technologies and to increase the amount of people receiving CGMs and insulin pumps.

10:00

Johann Lamont Lab The Convener · Glasgow
link

So if we want to quantify what the £2 million means, we would have to calculate what the boards would have to find for the VAT.

Gillian Gunn Scottish Government
link

There are differences in how the boards fund the technologies. The amounts that have been given will depend on which technologies they buy for individual people. A range of continuous glucose monitors is available, and a range of insulin pumps. Boards will purchase the ones that are most appropriate for the individuals that they see.

Johann Lamont Lab The Convener · Glasgow
link

If the Scottish Government is providing funding, would it not be reasonable for it to factor in how much extra it costs to deliver the technology? To me, it does not seem to be reasonable to say, “We are giving you this amount of money to address a problem but, as a consequence of that, you will have to find more money.” Presumably, when there is not much money, most health boards will have to incorporate the cost of VAT into the amount that they have been given and therefore there might be a reduction in the number of people who will be able to be helped.

Professor Leitch
link

The boards have the money to spend as they want on this subject. Let us be careful not to confuse that with what the petition is about, which is flash glucose monitoring.

Johann Lamont Lab The Convener · Glasgow
link

I am not confusing the issue. Please forgive me. I understand what the difference is, because we have been given the evidence on that. I am asking whether, when the Scottish Government provides funding, it calculates the VAT implications at that point, and whether it therefore gives a transparent report on how many people will be able to be helped by the moneys that are being provided.

Professor Leitch
link

The money would come along with a commitment and a target for the number of people who would get insulin pumps and continuous glucose monitoring. Such numbers are public and published, and we are on target to meet them.

Johann Lamont Lab The Convener · Glasgow
link

That includes the cost of VAT, then.

Professor Leitch
link

Correct.

Johann Lamont Lab The Convener · Glasgow
link

Are you suggesting that NHS Forth Valley is mistaken in thinking—as it has stated—that it was getting X amount of money to provide X amount of support, but then discovered that it had to pay the VAT as well.

Professor Leitch
link

I am suggesting not that it is mistaken but that the money that it got to meet its target—for want of a better expression—for continuous glucose monitoring and insulin pumps has enabled it to reach its target. That will have to include VAT.

Johann Lamont Lab The Convener · Glasgow
link

It included VAT. So when NHS Forth Valley says that it did not realise that, it is wrong.

Professor Leitch
link

No. I am sure that it is telling the truth in saying that it did not realise that. I am not suggesting that it is lying.

Professor Leitch
link

Perhaps there is a misunderstanding between the two organisations—us and it.

Johann Lamont Lab The Convener · Glasgow
link

Is it unusual for VAT not to be factored in?

Professor Leitch
link

Many of the technologies that are purchased by the national health service include VAT. When we give money for a specific purpose or technology such as this—which we do not do very often, as we give boards a block grant to spend for the health of their populations—that money comes with aims and targets for each board to meet. That has to include the whole costs of the technology.

Johann Lamont Lab The Convener · Glasgow
link

So your targets were informed by the costs with VAT.

Professor Leitch
link

Correct.

Johann Lamont Lab The Convener · Glasgow
link

So it is not the case that health boards would separately have to find the money for VAT, which is what we heard earlier.

Professor Leitch
link

That is my understanding. I am happy to talk to NHS Forth Valley and correct any confusion.

Johann Lamont Lab The Convener · Glasgow
link

It seems to me to be a significant issue. We seem to have had two separate messages from the evidence that we have had already.

Let us move on to Angus MacDonald’s question, and we will come back to that point.

Angus MacDonald SNP Falkirk East
link

Good morning, panel. I have taken on board your clarification regarding funding for continuous glucose monitoring. When the committee was on its fact-finding visit to Dumfries and Galloway a few months ago, we discussed the cost of using glucose monitoring technology compared with that of traditional pinprick blood tests. We heard from diabetes sufferers and pharmacists that there was not much of a cost difference, but a consultant whom we met suggested that there was. That suggestion took account of access to peripherals, such as testing strips. Can you clarify for us what cost analysis you have undertaken on the costs of pinpricking compared with those of continuous glucose monitoring and flash glucose monitoring?

Richard Shearer Scottish Government
link

Because of the population that continuous glucose monitoring is targeted at, the most important thing is matching the technology to the individual. We know that it costs more, but that is because of the additional features, such as the alarms and the ability to be linked to a pump. On that basis, the cost analysis is more to do with what it costs to deliver. We know that there is an offset against it.

With flash glucose monitoring, there is a point at which it costs the same as, or less than, finger pricking, and that point is between eight and 10 finger pricks a day. For someone who does fewer than eight finger pricks a day, flash glucose monitoring costs marginally more, whereas it costs marginally less for people who do more pricks than that because, with flash, there is a fixed cost. Regardless of how often someone scans, the cost of scanning does not increase, but if they finger prick, there is a cost attached to each test strip.

Maurice Corry Con West Scotland
link

Good morning, panel. The 2017-18 guidance that was provided to NHS boards on future funding said that there would be an increased emphasis on continuous glucose monitoring devices, but the more recent 2018-19 guidance does not contain a similar statement. Why is that? What other guidance might NHS boards be provided with as regards future funding for such devices?

Richard Shearer Scottish Government
link

The initial letter went out at a time when we planned to initiate fewer CGM devices in the first year than we ended up initiating. After that letter was sent out, discussion took place with boards, which had identified marginally fewer people for insulin pumps than they had been able to identify for CGM devices, so we ended up funding roughly 50 per cent more CGM devices in the first year than we had planned to. We are now on a trajectory of initiating about the same number of devices, or slightly more, each year rather than the increasing trajectory that we had originally planned on.

Professor Leitch
link

It is important with all new technology such as CGM to use it with the appropriate people. Only quite a small number of people benefit from that much more expensive technology—people who have regular hypoglycaemic attacks and who cannot notice when their blood sugars are going off, for want of a better expression. Although continuous glucose monitoring is slightly more invasive in nature, it is very useful in that small group of people, because we can link it technologically to the insulin pump to control their insulin.

Gillian Gunn Scottish Government
link

The phased approach for continuous glucose monitors is enabling us to make sure that we have a workforce that has the appropriate skills. That is an important part of the introduction of new technologies.

Johann Lamont Lab The Convener · Glasgow
link

Is it the eventual ambition to end pinprick testing?

Professor Leitch
link

Do you mean globally?

Professor Leitch
link

With the present technologies that are available, it would appear that pinprick monitoring will continue for the foreseeable future until cheaper and easier-to-use technology becomes available.

Johann Lamont Lab The Convener · Glasgow
link

But if we discount the issue of cost, pinprick testing would be recognised as less than optimal for people.

Professor Leitch
link

Indeed. If the diabetes community—patients, families and medical staff—can find a technology that fulfils that purpose that is non-invasive, that will be a big change. We appear to be in a period of technological advancement that is moving us towards that.

Richard Shearer Scottish Government
link

CGM, for example, requires calibration through finger pricking on a daily basis, and the Driver and Vehicle Licensing Agency has rules on finger pricking and driving. In future, as Jason Leitch said, we hope to have a non-invasive approach, but at the moment all the technology that we have still requires the use of finger pricking.

Maurice Corry Con West Scotland
link

From reports that I have read, I understand that we are not that far from non-invasive technology being available—I am talking about a matter of a couple of years. Is that correct?

Richard Shearer Scottish Government
link

Are you referring to the artificial pancreas?

Maurice Corry Con West Scotland
link

Well, in layman’s terms, I am talking about not having to pinprick.

Richard Shearer Scottish Government
link

That is potentially the case, but the artificial pancreas is still at an early testing stage. As with all technology, we would expect it to go through comprehensive clinical trialling. There would then be the issue of roll-out, and manufacturers would have to be able to achieve the required scale of numbers. The clinical appropriateness of any technology for particular sub-groups of the condition would also have to be considered.

Rona Mackay SNP Strathkelvin and Bearsden
link

Professor Leitch, you said in your opening statement that the Scottish health technologies group is undertaking a national appraisal of FreeStyle Libre as there is a lack of published data about the clinical and cost effectiveness of flash glucose monitoring. Will you explain why FreeStyle Libre was added to the Scottish drug tariff if there is insufficient information about its clinical or cost effectiveness?

Professor Leitch
link

The Scottish drug tariff is a different bar from the bar for getting into formularies. The tariff requires safety and no detriment, but it does not take account of clinical or cost effectiveness. It is the first step towards delivery as a prescribed medicine or device. The next step is that local formulary committees in boards make a decision—yes or no—for their local formularies. That is informed by local evidence from inspectors, pharmacists and clinicians, but we try to help nationally by doing national investigations using the SIGN guidelines; we use the SMC for drugs and the Scottish health technologies group for devices. In this case, that has happened pretty quickly. It joined the tariff in November, and in July we will get a report from the health technologies group, which will give us more evidence—or combined evidence—that will allow us to go back to boards and continue the journey.

Rona Mackay SNP Strathkelvin and Bearsden
link

So a drug is added to the drug tariff before all of that has been scoped out.

Professor Leitch
link

Correct. It is the same as in the other UK countries. Each country has its own drug tariff. For medicines, you get European approval, then individual country approval in the drug tariff, and then it is added to formularies. In England, the regional clinical commissioning groups decide what is in the formularies, and in Scotland the health boards decide.

Rona Mackay SNP Strathkelvin and Bearsden
link

You said that the appraisal is due to be published in July. Have you had any engagement with the group on the findings so far? Do you have an indication of what they might be?

Professor Leitch
link

I do not. The group deliberately acts independently. It is part of Healthcare Improvement Scotland, but it takes independent evidence from independent witnesses. I am led to believe that I will get the findings in the next few weeks.

Rachael Hamilton Con Ettrick, Roxburgh and Berwickshire
link

I have had letters from constituents about FreeStyle Libre. In April, I received a letter from Shona Robison, which states:

“the Scottish Government is committed to increasing the access to Continuous Glucose Monitors (CGM), which when used in combination with insulin pump therapy, has been clinically proven to significantly reduce NbA1c levels and hypoglycaemic episodes.”

The 2017-18 guidance that was provided to NHS boards stated that there was increased emphasis on continuous glucose monitoring devices, but the 2018-19 guidance—the most recent guidance—does not contain a similar statement. Why is that? What other guidance have NHS boards been given on funding, given that the guidance for the two years differs?

Richard Shearer Scottish Government
link

In the second letter—the 2018-19 letter—we sought not to repeat the 2017-18 letter, in order to make it simpler for boards. The principles were established in the first letter and the first round of funding. We sought to clarify the similarities with the first year—the target group is the same—and set out the funding, in order to reduce the scale of the correspondence.

Professor Leitch
link

To be clear, I add that we still believe what was in the first letter. We believe that continuous glucose monitoring connected to insulin pumps is appropriate for a small number of the difficult-to-control group of diabetics—that is not a particularly pleasant phrase—and provides a real step-change in their lifestyles: they can live normal lives where previously they could not. We still believe that technology to be clinically effective and cost effective for that group.

Rachael Hamilton Con Ettrick, Roxburgh and Berwickshire
link

Can you clarify what the future will be? You said that the treatment is appropriate for the difficult-to-control group. What is the future direction for NHS boards?

10:15

Richard Shearer Scottish Government
link

For CGM, we review the guidance that we have issued in relation to the group that we are targeting our funding at. We do that with our national diabetes specialist nurse, who is focused on technology and is assisting boards in the roll-out and implementation of CGM and insulin pumps. That will ensure that we are still focused on the correct group. It might be that we will move on to the next priority group. For example, if we have managed to initiate CGM for as many of the hypoglycaemic unawareness group as are willing to take on the technology, we will look at the next clinically indicated group beyond that, in terms of risk.

Rachael Hamilton Con Ettrick, Roxburgh and Berwickshire
link

What is the guidance to the boards on the funding part of that?

Richard Shearer Scottish Government
link

That guidance will come in the annual director’s letter. If we get to the point at which we move to the next indicated risk group, information with regard to the annual funding will be contained in the director’s letter.

Emma Harper SNP South Scotland
link

Good morning. I am co-convener of the cross-party group on diabetes. I have type 1 diabetes and am a pump user and an intermittent flash monitor user, so I understand the technology and how it works. I have a constituent who has a seven-year-old who is not having seizures at night any more, following the introduction of flash monitoring, and that is fantastic.

I am curious about how we support and educate the patients, nurses and staff. NHS Dumfries and Galloway has set criteria that people must meet in order to qualify for a flash monitor: they have to do six tests a day, they have to agree to the uploading of their results and they have to have attended the dose adjustment for normal eating—DAFNE—course. The process is complicated and the staff will have to be trained if they are to support people with type 1 diabetes. What are your thoughts on that?

Professor Leitch
link

You raise an important point about the new technologies. The patients and families have to be trained, which has implications for them and the training of the diabetes nurses and general practitioners, as, presently, the technology is provided in secondary care. Further, we have to ensure that our staff keep up with changes in those technologies. The Scottish diabetes group and third sector organisations help us with all of that.

It is absolutely correct that boards will set criteria for the inclusion of whatever that new technology is, just as they would for insulin pumps or any other device for a home-based process, such as dialysis. We will provide guidance, as we often do, either through the work of Healthcare Improvement Scotland or through the Scottish Government, in order to equalise that guidance as best we can across the territorial boards.

Emma Harper SNP South Scotland
link

I love the idea that technology is reducing the need for finger sticks, because that process causes people pain. However, I assume that we still have to use the finger stick process as a way to calibrate the flash monitors, which means that we will not completely eliminate finger sticking. Is that correct?

Professor Leitch
link

That is correct at present. I imagine that the companies are working tirelessly behind the scenes on technologies that will eventually replace the more invasive elements of diabetes care. Just now, the machines require a test to enable them to calibrate themselves. When people go for secondary care diabetes care, they have actual blood tests, not pinprick tests. In order to monitor their continuous care, blood testing is required. I cannot see that requirement disappearing soon.

Emma Harper SNP South Scotland
link

I assume that, as more people are introduced to CGM and flash, boards will monitor their haemoglobin A1c levels to show that there is an improvement, because long-term blood glucose control will reduce the complications that are associated with diabetes. In the long term, there will be cost savings.

Professor Leitch
link

That is correct, if what you say comes true. That is why the SCI-diabetes process is important. I am glad that NHS Dumfries and Galloway wants to know the data. As you will know, because you are probably on SCI-diabetes, that system monitors eye problems, foot problems and hypoglycaemic admissions. We will be able to relate that to the technology that the individual is using, which will give us more information. At present, the Scottish health technologies group can really look only at published evidence, as it does not have Scotland-wide evidence from thousands of patients, but eventually it will have that.

Johann Lamont Lab The Convener · Glasgow
link

I have a couple of questions to conclude the session. The committee has heard previously that the SIGN guidelines for diabetes type 1 management are out of date and have not kept up to date with technology. How do you respond to that?

Gillian Gunn Scottish Government
link

We are engaging with Healthcare Improvement Scotland to look at the SIGN guidelines. We have sought advice and are progressing that work with Healthcare Improvement Scotland and SIGN.

Gillian Gunn Scottish Government
link

There is no timescale at the moment. We are looking to see how SIGN guidelines may be updated. We are aware that the National Institute for Health and Care Excellence guidance has recently been updated and we are looking across all the national guidance that is currently available.

Professor Leitch
link

I undertake to answer that question more fully. I will ask SIGN.

Professor Leitch
link

I will ask for a timescale.

Johann Lamont Lab The Convener · Glasgow
link

It would be useful to know that. I accept that there may be a moving target but, when you say that you are going to do something, it is always helpful to have a timescale.

Professor Leitch
link

SIGN has a waiting list and a pipeline for new guidelines and for updating its guidelines. The one that you refer to will be in that pipeline somewhere. SIGN is also reviewing the nature of how it creates guidelines, exactly because of the pace of change in healthcare. The traditional method is to have quite a long period of evidence gathering of, sometimes, two or three years. As you say, however, the situation can move during that time, so SIGN needs a slightly more agile version. It may change its processes, which would help for diabetes care, asthma care and other issues.

Johann Lamont Lab The Convener · Glasgow
link

It would be useful to get more information. I understand the point that technology is a moving feast. We can be sorting a problem when there is perhaps something already developed that changes the landscape completely.

I understand that ministers have asked NHS boards to provide quarterly updates on the progress made in relation to the additional funding that we spoke about. What does that information tell you and what do you understand the continuing challenges for health boards to be in relation to how they use the funding?

Gillian Gunn Scottish Government
link

The information from boards tells us that they are on track to meet the targets that we have set. Going forward, we know that the cost of the technologies has an impact on boards, which is why we have been supporting the process nationally. We need to work with the boards as we progress through this period of funding so that they can embed the costs in their resources in future.

Johann Lamont Lab The Convener · Glasgow
link

So the funding will be mainstreamed at a later stage.

Gillian Gunn Scottish Government
link

Insulin pumps for children are already mainstreamed. The additional funding for adult pumps is to help boards to further progress what is already mainstreamed in their budgets.

Johann Lamont Lab The Convener · Glasgow
link

Will you continue to keep an eye on the targets and whether they have been met?

Gillian Gunn Scottish Government
link

Yes.

Johann Lamont Lab The Convener · Glasgow
link

Thank you very much for your responses. I appreciate that you had to come along at short notice.

Do members have any comments or suggestions for action, given what we have heard?

Rona Mackay SNP Strathkelvin and Bearsden
link

Obviously, we will reflect on the evidence that we have heard, which was useful. We should continue the petition until the national appraisal has been published, which will happen shortly, and then we can take stock of where we are.

Johann Lamont Lab The Convener · Glasgow
link

It might be worth while to invite the new cabinet secretary to come at some point to give us an update from her perspective on where we are on the issue. Part of it is about testing whether the funding is adequate to meet the targets and whether there continue to be issues around that, but there is also the issue that the guidance is behind the technology, so it would be useful to hear what progress there has been on that, as well.

We are agreeing to continue the petition. We will reflect on the evidence that we have heard and we may factor in another session with the new cabinet secretary to allow her to respond to some of the submissions that will, no doubt, follow this session. As I said, the petitioner will have an opportunity to submit comments on what we have heard today.

I thank our witnesses again. I suspend the meeting briefly to allow them to leave.

10:24 Meeting suspended.

10:29 On resuming—

  1. 09:15 New Petitions Petitions · 71
  2. 09:30 New Petitions Petitions · 5
  3. 09:30 New Petitions Petitions · 4
  4. 09:30 Continued Petitions Petitions · 86
  5. 10:15 Continued Petitions Petitions · 11
  6. 10:45 Continued Petitions Petitions · 22
  7. 10:45 Continued Petitions Petitions · 11
  8. 10:45 Continued Petitions Petitions · 9
  9. 10:45 Continued Petitions Petitions · 12
  10. 10:45 Continued Petitions Petitions · 11

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.